Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2013.0055
复制
发表时间：
2013-04-01
影响因子：
13.4
通讯作者：
Ho, Maria
中科院分区：
文献类型：
--
作者：
Coit, Daniel G.;Andtbacka, Robert;Ho, Maria
NCCN黑色素瘤指南提供了关于黑色素瘤患者临床管理的多学科建议。这份NCCN指南洞察报告强调了最近值得注意的更新。其中最重要的是令人兴奋的新药物ipilimumab和vemurafenib用于治疗晚期黑色素瘤。NCCN小组还包括伊马替尼作为KIT突变肿瘤的治疗和聚乙二醇干扰素α-2b作为辅助治疗的选择。同样重要的是根据前哨淋巴结转移的风险对早期病变的初始分层进行修订，并修订了对低风险组使用前哨淋巴结活检的建议。最后，NCCN专家组就阐明成像在黑色素瘤患者检查中的作用达成了临床共识。（JNCCN 2013;11：395-407）
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma. (JNCCN 2013;11:395-407)